Skip to main content
OpenTrials
Completed

NCT Number: NCT04079998

Procellera® Compared to Standard of Care Treatment in Mitigating Biofilm Formation in Acute Trauma and Burn Wounds

The objective of the study is to evaluate Procellera® , a novel FDA approved antimicrobial wound dressing in a prospective, randomized, controlled clinical study. The hypothesis is that when the dressing is moistened, the low electric field created by moisture-activated elemental silver and zinc electro-couple will prevent formation of biofilm in wounds or to disrupt existing biofilm.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Brooke Army Medical Center

Fort Sam Houston, Texas, 78234, United States

About this study

The healing of traumatic wounds, to include burns, can be compromised by the presence of infection so efforts are made to prevent or diagnose infection early in order to mitigate the negative impact on healing. Electric stimulation has previously been shown to have both bacteriostatic and bactericidal effects in wounds. Until now, administering low intensity electric field/micro-current as a therapy to mitigate biofilm infection and to improve wound healing was not feasible. In this study the investigators will use Procellera® , a FDA approved fabric based wireless electroceutical dressing (WED) consisting of a silver-zinc electro-couple for the prevention of wound biofilm formation. The dressing generates a low electric field (~1V) upon activation by a moist environment, which mitigates biofilm formation and promotes wound healing. The objectives of the study are to evaluate the efficacy of a wireless electroceutical dressing to prevent the formation or disrupting existing biofilms. The investigators will conduct a prospective, randomized controlled clinical trial using the Procellera® dressing compared to the standard of care. Treatment sites will be randomized to either receiving Procellera® or the standard of care treatment. Objective measurements and assessments will be completed during subject follow-up visits for up to one month post treatment. This includes biopsies to calculate bacterial load by assessing colony forming unit (CFU) count and bacterial film visualization using scanning electron microscopy, histology, clinical assessment of infection, Transepidermal Water Loss (TEWL) and wound photography.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18-65 years of age
  • Willing and able to provide informed consent
  • Participant has acute partial-thickness or full-thickness wounds caused by trauma or partial-thickness burns that are ≥ 300 cm2 in size in one contiguous area or two separate wound sites ≥ 150 cm2 each

Exclusion criteria

  • Pregnancy
  • Prisoner
  • Active malignancy or immunosuppressive therapy
  • Current systemic steroid use
  • Known allergy or sensitivity to silver or zinc
  • Participant's proposed study wound site has any of the following conditions:
  • Location is on the hands, face or feet
  • Full-thickness burn wounds
  • Exposure of visceral organs
  • Exposure of hardware or prosthetic exposure

Treatment and study plan

Procellera®

Device

Application of Procellera® dressing.

Standard of care

Other

Application of standard of care dressings as prescribed.

Primary outcomes

  1. Presence of biofilm

    Time frame: Day seven

    Presence of biofilm will be assessed by obtaining a wound biopsy and analyzing with Scanning Electron Microscopy.

  2. Rate of eradication of biofilm production

    Time frame: Day 7

    Presence of biofilm will be assessed by obtaining a wound biopsy and analyzing with Scanning Electron Microscopy.

Secondary outcomes

  1. Incidence of infection

    Time frame: Day 0-30

    Wounds will be assessed for the presence of clinical evidence indicating infection.

  2. Percent epithelialization

    Time frame: Day 7

    The percentage of epitheliazation will be assessed utilizing clinical assessments and the Silhouette Star wound camera.

  3. Quality of healing

    Time frame: Day 30

    Quality of healing post-epithelialization as measured by the validated Patient Observer Scar Assessment Scale (POSAS)

  4. Quantitative bacterial load calculation

    Time frame: Day 7

    Quantitative bacterial load will be assessed by obtaining a wound biopsy and analyzed by performing colony forming unit counts

  5. Incidence of adverse events

    Time frame: Day 0-30

    The incidence of adverse events will be reported to assess safety.

Sponsors and collaborators

Lead sponsor

The Metis Foundation

Other

Collaborators

  • Indiana University

Registry information

Official study title

A Prospective, Randomized, Controlled Study to Determine the Superiority of a Fabric-based Wireless Electroceutical Dressing, Procellera® Compared to Standard of Care Treatment in Mitigating Biofilm Formation in Acute Trauma and Burn Wounds

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Sep 6, 2019
Registry last updated
Jan 22, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.